This isn’t current, but it clarifies what Dr. Green’s opinion on senolytics was in January of 2021:
LE: What are some effective senolytics?
Dr. Green: The main three senolytics I use are dasatinib, fisetin, and quercetin. Dasatinib is the generic name for Sprycel®, a drug approved since 1996 for the treatment of leukemia. Fisetin and quercetin are flavonoids present in fruits and vegetables. They’re sold over the counter and are known to be very safe.
My method is to use all three: 100 mg dasatinib for three days, 1,000 mg of regular quercetin for three days, 1,500mg of regular fisetin for three days. That’s a maximum dose. Patients can begin with a smaller dose and determine sensitivity.
There are now two human studies and more than 20 animal studies regarding dasatinib’s role as a senolytic. Quercetin has been used in two human studies, and all mouse studies with dasatinib included quercetin. Fisetin had an excellent result in a 2018 mouse study. It was even more effective than quercetin, and there are several human studies using fisetin now listed on: www.clinicaltrials.gov. There have been no apparent harmful effects from long-term removal of senescent cells.
LE: What do studies of senolytics show?
Dr. Green: In mouse studies, removal of senescent cells improves cardiac function and reduces cardiovascular disease, alleviates frailty and muscle weakness, decreases osteoporosis, improves running endurance, decreases fatty liver disease and lung disease, decreases Alzheimer’s-like dementia, and in old mice, increases lifespan by 36%.
The two most recent human studieswere done at the Mayo Clinic in 2019. One showed that a combination of 100 mg of dasatinib and 1,000 mg of quercetin, given orally for three days, removed senescent cells in people with diabetic kidney disease. This showed that senolytics may work similarly in humans as they do in mice.
The other study showed that 100 mg of dasatinib and 1,250 mg of quercetin, given for three consecutive days each week for three weeks, alleviated physical dysfunction and improved walking distance and speed in patients with idiopathic pulmonary fibrosis (a lung disease that makes it difficult to breathe). This demonstrated that some of the results in mice can be seen in humans.
LE: What conditions do you think can be treated with senolytics?
Dr. Green: In general, any condition or disease that gets worse with age or has increased incidence with age is likely a senescent-cell-related condition and may respond to treatment with senolytics.
This includes:
- Aging,
- Cancer,
- Cardiovascular disease,
- Alzheimer’s disease and neurodegeneration,
- Chronic lung disease and emphysema,
- Chronic kidney disease,
- Non-alcoholic fatty liver disease,
- Obesity and metabolic syndrome,
- Osteoarthritis and osteoporosis,
- Eye cataracts,
- Muscle frailty,
- And more.
LE: Besides senescent cells, you mentioned that the protein mTOR plays a role in aging. Can you explain that?